Purpose: mRNA degradation is an important regulatory step for controlling gene expression and cell functions. Genetic abnormalities involved in mRNA degradation genes were found to be associated with cancer risks. Therefore, we systematically investigated the roles of genetic variants in the general mRNA degradation pathway in lung cancer risk. Experimental design: Meta-analyses were conducted using summary data from six lung cancer genome-wide association studies (GWASs) from the Transdisciplinary Research in Cancer of the Lung and additional two GWASs from Harvard University and deCODE in the International Lung Cancer Consortium. Expression quantitative trait loci analysis (eQTL) was used for in silico functional validation of the identified significant susceptibility loci. Results: This pathway-based analysis included 6816 single nucleotide polymorphisms (SNP) in 68 genes in 14 463 lung cancer cases and 44 188 controls. In the single-locus analysis, we found that 20 SNPs were associated with lung cancer risk with a false discovery rate threshold of <0.05. Among the 11 newly identified SNPs in CNOT6, which were in high linkage disequilibrium, the rs2453176 with a RegulomDB score "1f" was chosen as the tagSNP for further analysis. We found that the rs2453176 T allele was significantly associated with lung cancer risk (odds ratio ¼ 1.11, 95% confidence interval ¼ 1.04-1.18) in the eight GWASs. In the eQTL analysis, we found that levels of CNOT6 mRNA expression were significantly correlated with the rs2453176 T allele, which provided additional biological basis for the observed positive association. Conclusion: The CNOT6 rs2453176 SNP may be a new functional susceptible locus for lung cancer risk.
INTRODUCTION
Lung cancer is one of the most frequently diagnosed cancers with about 1.8 million new lung cancer cases reported in 2012 worldwide, accounting for about 13% of total cancer diagnoses [1] . In the United States, 224 390 new lung cancer cases are estimated to occur in 2016 [2] . In addition to other factors, such as occupational and environmental carcinogens, cigarette smoking is the major risk factor for lung cancer [3, 4] , but not all smokers develop lung cancer, which suggests that genetic predisposition play an essential role in the lung carcinogenesis [5] .
In recent years, some genome-wide association studies (GWASs) of lung cancer have been conducted, and a number of genetic variants, that is, single nucleotide polymorphisms (SNPs), have been found to be associated with lung cancer risk. For example, the significant susceptibility loci associated with lung cancer risk include 5p15.3 (rs401681, rs4975616, and rs402710 in CLPTM1L and rs2736100 in TERT) [6] [7] [8] [9] [10] [11] , 6p21.3 (rs3117582 in BAG6 or APOM and rs2395185 in HLA-DRB5 or HLA-DRB9) [6, 8, 9, 11] , 6q22.1 (rs9387478 in RAP1BP3 or DCBLD1) [11] , and 15q25.1 (rs8034191 in HYKK and rs1051730 in CHRNA3) [6, 8, 9, [12] [13] [14] [15] . Among these SNPs, rs1051730, rs3117582, and rs2736100 were found to be specifically associated with risk of lung adenocarcinoma (AD) [9] , whereas rs12296850 (mapped to 12q23.1) in SLC17A8 or NR1H4 was found to be a susceptibility locus for risk of squamous cell carcinoma (SC) [16] . Interestingly, the vast majority of the SNPs identified by GWASs are in introns or intergenic regions, and their functional evidence is limited. In the present study, we employed the pathway-based strategy that dramatically decreases the number of SNPs to be analyzed and thus significantly reduced multiple testing with the aim to identify possible lung cancer risk-associated functional SNPs that may have not been revealed by previous lung cancer GWASs.
The degradation of mRNA is an important regulatory step for controlling gene expression and cell functions [17] . The general cytoplasmic mRNA decay pathway usually begins with the deadenylation, which removes the poly(A) tail Ccr4-Not complex [18] , followed by degradation of mRNA proceeding in two directions of 5 0 -3 0 or 3 0 -5 0 . The 5 0 -3 0 mRNA degradation initiates with decapping N 7 -methylguanosine (m 7 G) cap mainly by DCP1/DCP2 proteins and subsequently degraded by the exoribonuclease Xrn1, while the 3 0 -5 0 mRNA degradation is mainly catalyzed by 10-12 subunit exosome [19, 20] .
Some studies suggest that genetic abnormalities of genes involved in the general mRNA degradation pathway may be associated with lung cancer. For example, various genetic variants in LSM2-LSM8, which encode cofactors for mRNA decapping, were recently found in lung cancer cell lines [21] . Therefore, we hypothesize that genetic variants of the general mRNA degradation pathway are associated with lung cancer risk. To test the hypothesis, we conducted the comprehensive meta-analysis of the eight published lung cancer GWASs from the International Lung Cancer Consortium (ILCCO)-Transdisciplinary CNOT1, CNOT10, CNOT2,   CNOT3, CNOT4, CNOT6, CNOT6L, CNOT7,  CNOT8, DCP1A, DCP1B, DCP2, DCPS, DDX6,  DIS3, EDC3, EDC4, ENO1, ENO2, ENO3, EXOSC1,  EXOSC10, EXOSC2, EXOSC3, EXOSC4, EXOSC5,  EXOSC6, EXOSC7, EXOSC8, EXOSC9, HSPA9,  HSPD1, LSM1, LSM2, LSM3, LSM4, LSM5, LSM6,  LSM7, MPHOSPH6, NAA38, PAPD7, PAPOLA,  PAPOLB, PAPOLG, PARN, PATL1, PNPT1, RQCD1,  SKIV2L, SKIV2L2, TTC37, WDR61, XRN1, XRN2,  ZCCHC7 .
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MATERIALS AND METHODS
Study Populations
The first part of the study populations came from the TRICL consortium, which included 12 160 lung cancer cases and 16 838 controls (all Europeans) of six previously published GWASs from the MD Anderson Cancer Center (MDACC), the Institute of Cancer Research (ICR), the National Cancer Institute (NCI), the International Agency for Research on Cancer (IARC), Toronto study from Samuel Lunenfeld Research Institute study (Toronto), and the German Lung Cancer Study (GLC) [22] . The second part of the study populations included GWASs of European ancestry from Harvard Lung Cancer Study (984 cases and 970 controls) [23] and Icelandic Lung Cancer Study (deCODE) (1319 cases and 26 380 controls) [15] of the ILCCO. Written informed consents were achieved for all participants, and the present study was approved by each institutional review board of the participating institutions.
GWAS Genotyping and Imputation
Genotyping in the eight GWASs was performed by Illumina HumanHap 317, 317 þ 240S, 370Duo, 550, 610, or 1M arrays. The imputation was conducted by IMPUTE2 v2.1.1 or MaCH v1.0 software using the reference panel from the 1000 Genomes Project (phase I integrated release 3, March 2012). Standard quality control on samples was performed on all scans in the analysis, excluding any participants with low call rate (<90%), extremely high or low heterozygosity (P < 1.0 Â 10 À4 ), non-European (with the HapMap phase II CEU, JPT/CHB, and YRI populations as a reference) and imputed SNPs with an information score < 0.40 in IMPUTE2 or r 2 < 0.30 in MaCH.
Gene and SNP Selection
We first identified genes in the general mRNA degradation pathway from the Molecular Signatures Database [24] and the literature [18] . Overall, 75 genes located on autosomal chromosomes were selected, of which seven genes were pseudogenes or duplicates or withdrawn from updated NCBI. As a result, we then extracted genotype data of 68 genes (detailed in Table 1 ), including 2-kb of the flanking regions of each gene, from the GWAS datasets that also included those SNPs generated by imputation. The final metaanalysis contained 6816 SNPs and covariates provided by the TRICL consortium in the summary data with the following standards: genotyping rate ! 90%, minor allele frequency ! 1%, and Hardy Weinberg Equilibrium exact P-value ! 10
À5
. The overall workflow is shown in Figure 1 .
In Silico Functional Validation
Two in silico tools, SNPinfo (http://snpinfo.niehs. nih.gov/snpinfo/snpfunc.htm) [25] , RegulomeDB (http://regulomedb.org/) [26] , were used to predict potential functions. Expression quantitative trait loci (eQTL) analysis was performed by using the expression data of lymphoblastoid cell lines from 373 Europeans available in the 1000 Genomes Project (http://www.1000genomes.org/category/fre quently-asked-questions/gene-expression) [27] and
The Cancer Genome Atlas (TCGA) (https://tcgadata.nci.nih.gov/tcga/) [28] . In this TCGA dataset, 107 subjects had adjacent normal lung cancer samples used for the different expression testing, which were matched by 105 adjacent normal cancer tissue samples from the same individuals with the genotype data.
Statistical Analysis
Logistic regression model was used to calculate the odds ratios (ORs) and their 95% confidence intervals (CIs) in an additive genetic model with PLINK (v1.06) software. A meta-analysis with the inverse variance method was employed on the 6816 SNPs with Stata software (v12, State College, TX). Cochran's Q statistic was applied to test for heterogeneity and the I 2 statistic for the proportion of the total variation in the meta-analysis [29] . The fixed-effects model was Fixed effect models were used when no heterogeneity was found between studies (Q-test P > 0.100 and I 2 < 50.0%); otherwise, random effect models were used; c " þ " means a positive association, and "À" means a negative association.
used when there was no heterogeneity among GWASs (Q-test P > 0.100 and I 2 < 50%); otherwise, the random-effects model was used. Multiple testing correction was conducted with false discovery rate (FDR) with a threshold <0.050 [30] . A linear regression model was also performed to evaluate the correlation between SNPs and mRNA expression levels of the corresponding genes. A paired t-test was used to compare the mRNA expression levels of genes in the lung cancer and normal adjacent tissue from the TCGA database. LocusZoom (http://locuszoom.sph. umich.edu/locuszoom/) was applied to construct regional association plots using Europeans from the 1000 Genomes Project as the reference (phase I integrated release 3, March 2012) [31] . Haploview v4.2 was used to generate the Manhattan plot and LD plots [32] . All analyses were conducted with SAS (version 9.4; SAS Institute, Cary, NC) except for those specified otherwise.
RESULTS
Associations of the SNPs With Lung Cancer Risk
We first performed a meta-analysis in the TRICL database consisted of six previously published GWAS datasets with 12 160 cases and 16 838 controls. The basic information of these six studies is presented in Supplemental Table S1 . A total of 6816 SNPs in the pathway were extracted, of which 466 SNPs were associated with lung cancer risk at P < 0.05 in the additive model and 20 SNPs on LSM2, SKIV2L, and CNOT6 remained significantly associated with lung cancer risk with FDR < 0.050 after multiple testing corrections ( Figure 2A and Table 2 ). Among these SNPs, we excluded those of LSM2 and SKIV2L, because they were mapped to and in high LD with previously GWAS-reported locus at 6p21.33 [6, 8] . As a result, 11 SNPs of CNOT6 located at 5q35.3 were left for further analysis. In the LD analysis, these 11 SNPs shared moderate to high LD (r 2 ! 0.60, Figure 2B and C). We finally chose rs2453176 as the tag SNP, because it was significantly associated with lung cancer risk (OR ¼ (Table 2 ) and potentially functional according to function prediction and its imputation quality was the best among the 11 SNPs (Table 3) . We used the forest plot to illustrate the association between rs2453176 and lung cancer risk in the six GWASs (Figure 3) , and the rs2453176 T allele was associated with an increased lung cancer risk in five GWASs, except for the GLC GWAS.
We expanded our analysis to include additional two independent lung cancer GWASs (Supplemental Table S1 ). The deCODE GWAS validated our result of the CNOT6 rs2453176 tag SNP (OR ¼ 1.14, 95% CI ¼ 1.01-1.28, P ¼ 0.032), while the GWAS from Harvard University displayed the same trend as the GLC GWAS (OR ¼ 0.85, 95%CI ¼ 0.68-1.05, P ¼ 0.133) ( Figure 3 and Table 4 ).
As we combined the above results from the eight GWASs, the functional CNOT6 rs2453176 tag SNP was found to be significantly associated with an increased risk of lung cancer (OR ¼ 1.11, 95%CI ¼ 1.04-1.18, P ¼ 0.001) after the FDR correction ( Figure 3 and Table 4 ). 
Stratified Analyses by Lung Cancer Histology
Since lung cancer has different histological types that could have distinct biological behaviors, we performed AD and SC subgroup analysis and found that the rs2453176 T allele was associated with a borderlinely increased risk in AD (OR ¼ 1.13, 95%CI ¼ 1.00-1.27, P ¼ 0.050, Table 4 ), but it was significantly associated with SC risk (OR ¼ 1.12, 95% CI ¼ 1.03-1.22, P ¼ 0.006, Table 4 ). Because smoking is a major risk factor for lung cancer, we further stratified the data into smokers and non-smokers and found that that the rs2453176 T allele was associated with a significantly increased risk in smokers (OR ¼ 1.09, 95%CI ¼ 1.02-1.17, P ¼ 0.011, Table 5 ), while the allele was not statistically significant in nonsmokers (OR ¼ 1.10, 95%CI ¼ 0.89-1.36, P ¼ 0.363, Table 5 ). Homogeneity tests suggested that there was no heterogeneity between strata either in subgroups of histologic types or smoking status (Tables 4 and 5 , all P > 0.05).
Functional Validation by eQTL Analysis
Because the CNOT6 rs2453176 SNP was predicted with a score of "1f", suggesting the most confident functional annotation by regulomeDB [26] , we further explored the underlying molecular mechanism by performing the eQTL analysis. With mRNA expression data of lymphoblastoid cell lines from 373 Europeans available from the 1000 Genomes Project, We found that expected mRNA expression levels of CNOT6 were significantly decreased with an increased number of the rs2453176 T allele in both the additive (P ¼ 0.008) ( Figure 4A ) and dominant (P ¼ 0.007) ( Figure 4B ) models but not the recessive model ( Figure 4C ). However, only 105 subjects had both DNA and RNA samples tested in this dataset. We also used the 105 normal adjacent tissue samples in the TCGA to further explore the correlation between the rs2453176 genotypes and their corresponding mRNA expression levels, but we did not observe a statistical significance (P > 0.05) (Supplemental Figure S1A-C) . We also compared the mRNA expression level of CNOT6 in the 107 paired samples and did not find a statistically significant difference (P > 0.05) (Supplemental Figure S1D ).
DISCUSSION
In the present study, we found that a novel potentially functional susceptibility locus rs2453176 C>T of CNOT6 in the general mRNA degradation pathway was associated with an increased lung cancer risk in 14 463 cases and 44 188 controls. This association was further supported by a significant correlation between a decreased mRNA expression level and an increasing number of the A allele in the eQTL analysis.
Gene expression disorder is one of cancer hallmarks, and instability of mRNA may result in altered transcript/protein levels of oncogenes and tumor repressor genes [33] . The degradation of mRNA is a key step in controlling the expression of genes related to cell proliferation. For example, the CCR4-Not complex consists of highly conserved exoribonucleases and adaptor proteins that hydrolyze and shorten the poly(A) tail, which starts the initial and the rate-limiting step of mRNA degradation [18, [34] [35] [36] . Located at 5q35.3, CNOT6 encodes a protein that has a 3 0 -5 0 RNase activity and acts as a catalytic subunit of the CCR4-Not deadenylation complex [37] . Although it remains unclear how the catalytic subunit works during the deadenylation process, some studies reported that its expression level was associated with carcinogenesis or prognosis. For example, one study of lung cancer found that the CNOT6 overexpression in lung SC predicted a significantly less metastasis [33] . Another study of acute leukemia discovered that CNOT6 had a significantly lower expression in patients than in controls [38] . These two studies suggest that high expression levels of CNOT6 may promote the degradation of mRNA of some oncogenes and the suppression of cell proliferation in carcinogenesis.
In the present study, we identified that the CNOT6 rs2453176 T allele was associated with an increased risk of lung cancer, which was supported by the association of CNOT6 rs2453176 T allele with a decreased mRNA expression level in lymphoblastoid cell lines from 373 Europeans. This finding is consistent with the role of CNOT6 in lung cancer prognosis as previously described [33] . The ENCODE project data from University of California Santa Cruz show that the CNOT6 rs2453176 locus is located at the DNase I hypersensitive region (Supplemental Figure S2 ). Usually such an area has a loose chromatin structure and renders it a region with a high affinity for transcription factors (TFs). As a result, some TFs, including MAFK and MAFF, bind to this region in many cell types (Supplemental Figure S2 ). For example, MAFK and MAFF were found to form heterodimers with a series of TFs and suppressed gene transcriptions [39, 40] . Based on these, we speculate that the rs2453176 T allele may have a relatively high affinity with MAFK or MAFF and thus leads to the decreased mRNA expression of CNOT6. It is likely that a reduced quantity of CNOT6 may not be optimal in the mRNA degradation of some aberrant genes, which may in turn increases lung cancer risk, but these speculations need to be further investigated.
In the stratification analysis, rs2453176 was associated with lung cancer risk in both AD and SC subtypes, but it was significantly associated with cancer risk in the smokers but not in the non-smokers. Genetic susceptibility to smoking-related lung cancer risk may determine smoking behavior and tobacco metabolism [41] . Indeed, we found that the rs2453176 T allele was associated with a higher risk of lung cancer in smokers than in non-smokers. One Table 4 SUSCEPTIBILITY LOCI IN THE GENERAL mRNA DEGRADATION PATHWAY AND LUNG CANCER RISK study reported that smoking would enhance the activity of the GATA family [42] , and another study reported that nicotine would increase the expression of EP300 and promote the lung cancer growth [43] . From the Supplemental Figure S2 , GATA1, GATA2, and EP300 are the TFs that bind to the rs2453176 locus, possibly explaining why carriers of the rs2453176 T allele may have an increased risk of lung cancer in smokers than non-smokers. There are some limitations in the present study. First, we employed the Molecular Signatures Database [24] to define the general mRNA degradation pathway to be investigated, but we may have missed some newly discovered genes in the pathway. However, we searched the literatures and added genes as many as possible. Second, due to the data limitation, we had no access to family history and others factors that may have an impact on lung cancer risk. Third, we used the eQTL analyses from lymphoblastoid cell lines and normal adjacent tissue in TCGA database to validate the risk association. Although the results from the cell lines support our identified association, they may only reflect the baseline or genetically determined expression levels without exposure to smoking. The gene expressions in the normal adjacent lung tissues may be in some degree different from the normal lung tissue and did not support the association.
Overall, the present study of eight published GWASs identified a novel CNOT6 rs2453176 SNP in the general mRNA degradation pathway to be significantly associated with lung cancer risk in European populations, and the risk was more evident in smokers than in non-smokers. Although we used the publically available gene expression database from blood to confirm the biological significance of the variant, further functional 
